// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























2187 Abstracts

A Systematic Literature Review (SLR) of Clinical Outcomes after Stem Cell Transplantation (SCT) in Adult Acute Lymphoblastic Leukemia (ALL) Patients with or without Minimal Residual Disease (MRD)

Monica Turner - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Analysis of Genetic Abnormalities in Newly Diagnosed Acute Lymphoblastic Leukemia Patients at King Faisal Specialist Hospital & Research Centre

Osamah Khojah - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Poor Outcome of CRLF2 Rearranged Philadelphia Negative Acute Lymphoblastic Leukemia Adults Patients

Yasser H Elnahass - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Staining Pattern of Leukemic Lymphoblasts for Coagulation Factor XIII Subunit a Correlates with Clinical Outcome and B-Other Genotype in Childhood Acute Lymphoblastic Leukemia

Csongor Kiss - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups

Anna Ferrari - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis in Pediatric Hematologic Malignancies

Gerardo Lopez-Hernandez - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Mycophenolate mofetil

Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Post-Transplant Relapsed CD19 Positive Acute Lymphoblastic Leukemia: Systematic Review

Ceren Durer - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Blinatumomab

Medium-Dose VP-16 Intensified Conditioning Regimen Is Effective in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Feifei Sun - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Etoposide phosphate

The Comparison of Unmanipulated Bone Marrow Versus Peripheral Blood Haploidentical Stem Cell Transplantation in Adult Acute Leukemia: A Systematic Review and Meta-Analysis

Seren Durer - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Allogeneic Transplantation for Minimal Residual Disease Negative Acute Lymphoblastic Leukemia According to 2016 Who Classification: A Single Center Retrospective Analysis

Xingyu Cao - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

Heterogeneous Responses Among Ph+-B-ALLs to Imatinib with NRAS Mutant Being One Mechanism of Complete Resistance

Xiaoyu An - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Imatinib

Enhancing a Specialized Nursing Care Guidelines Improves Acute Lymphoblastic Leukemia Patients' Outcome during Induction Phase; A Developing Country Experience

Nesreen Fathy Hanafy - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Clinicians' Perspectives on Cure in Adult Acute Lymphoblastic Leukemia (ALL) Patients with Minimal Residual Disease (MRD) - Findings from a UK Delphi Panel

David Marks - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

The Importance of Patients and Caregivers Education to Prevent Central Line Associated Bloodstream Infections in Children with Malignancies: A Single Center Experience

Alessandro Di Gangi - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Efficacy and Tolerability of Tedizolid Phosphate in the Treatment of Mycobacterium Abscessus Infection among Pediatric Hematopoietic Stem Cell Transplant Recipients

Y. Kang - American Transplant Congress (ATC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Tedizolid phosphate

CD19/CD3 bispecific antibodies induce potent response against chronic lymphocytic leukemia cells ex vivo

Hannah Ruth Robinson - American Association of Immunologists (AAI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Blinatumomab

Combined inhibition of JAK/STAT and BCL2 during ex vivo NK cell expansion enriches a highly cytotoxic NK cell subset

Kirsti Lorraine Walker - American Association of Immunologists (AAI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Ruxolitinib phosphate

MERTK inhibition in the leukemia microenvironment promotes a therapeutic immune response to acute lymphoblastic leukemia

Kristen M Jacobsen - American Association of Immunologists (AAI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

L-Tyrosine

Selective TRAF over-expression enhances CD19-targeted 41BB CAR T function by increasing NF-κB

Gongbo Li - American Association of Immunologists (AAI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Mutation of the CD28 costimulatory domain confers increased CAR T cell persistence and decreased exhaustion

Justin C. Boucher - American Association of Immunologists (AAI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Interferon Gamma

Copyright © 2026. QuantiNova All rights reserved